ACP
VRTX icon

Aviance Capital Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

Aviance Capital Partners’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$201K Buy
+405
New +$179K 0.02% 380
2024
Q4 		– Sell
-830
Closed -$386K – 346
2024
Q3 		$386K Buy
830
+149
+22% +$71.6K 0.05% 244
2024
Q2 		$319K Buy
681
+114
+20% +$49.5K 0.05% 256
2024
Q1 		$237K Hold
567
– – 0.04% 283
2023
Q4 		$231K Buy
+567
New +$209K 0.05% 225

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Aviance Capital Partners's VRTX Position: Q2 2026 in Review

Aviance Capital Partners opened a new position in Vertex Pharmaceuticals (VRTX) in Q2 2026: 405 shares worth $201K. The stake represents 0.02% of the portfolio and ranks #380 among its holdings. This is a return to the name: Aviance Capital Partners previously reported a position in VRTX as recently as Q3 2024.

Aviance Capital Partners first reported a position in VRTX in Q4 2023 and has held it in 5 quarters since. The position peaked at $386K in Q3 2024. 1,758 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Aviance Capital Partners held 405 shares of Vertex Pharmaceuticals worth $201K as of Q2 2026.
  • Vertex Pharmaceuticals was a new Aviance Capital Partners position in Q2 2026.
  • Vertex Pharmaceuticals made up 0.02% of Aviance Capital Partners's portfolio in Q2 2026, its #380 holding.
  • Aviance Capital Partners first reported a position in Vertex Pharmaceuticals in Q4 2023 and has held it in 5 quarters since.
  • Aviance Capital Partners's Vertex Pharmaceuticals position peaked at $386K in Q3 2024.
  • 1,758 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Aviance Capital Partners's 13F filing for Q2 2026, filed 31 Jul 2026.